Literature DB >> 26372859

Pneumococcal vaccination coverage among persons ≥65 years--United States, 2013.

Alissa C O'Halloran1, Peng-Jun Lu2, Tamara Pilishvili3.   

Abstract

BACKGROUND: Invasive pneumococcal disease is a major cause of illness in the United States, and rates are higher among persons ≥65 years. Pneumococcal vaccination has been recommended to adults ≥65 years since 1997.
METHODS: Data from the 2005-2013 Behavioral Risk Factor Surveillance System were analyzed. Weighted estimates of pneumococcal vaccination coverage were calculated by state and race/ethnicity and tests for linear trend were performed.
RESULTS: In 2013, the median state vaccination coverage among adults ≥65 years was 69.5%, and coverage ranged from 61.9% in New Jersey to 75.6% in Oregon. Coverage overall among non-Hispanic whites (71.1%) was higher than coverage for non-Hispanic blacks (57.7%), Hispanics (51.9%), and non-Hispanic persons of other race (65.4%). Coverage increased from 2005 to 2013 overall and by racial/ethnic subgroups.
CONCLUSION: Although pneumococcal vaccination coverage has improved in the past several years, coverage remains below the Healthy People 2020 target of 90% and racial/ethnic disparities exist.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Pneumococcal vaccination

Mesh:

Substances:

Year:  2015        PMID: 26372859     DOI: 10.1016/j.vaccine.2015.09.002

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Pneumococcal vaccination coverages among low-, intermediate-, and high-risk adults in Catalonia.

Authors:  Angel Vila-Corcoles; Olga Ochoa-Gondar; Imma Hospital; Cinta de Diego; Eva Satué; Jordi Bladé; Xabier Ansa; Jorge A Guzmán; Elisabet Salsench; Francisca Ramos
Journal:  Hum Vaccin Immunother       Date:  2016-07-25       Impact factor: 3.452

2.  Pneumococcal Vaccination Among Medicare Beneficiaries Occurring After the Advisory Committee on Immunization Practices Recommendation for Routine Use Of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults Aged ≥65 Years.

Authors:  Carla L Black; Walter W Williams; Rob Warnock; Tamara Pilishvili; David Kim; Jeffrey A Kelman
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-07-14       Impact factor: 17.586

3.  Racial/Ethnic Differences in Influenza and Pneumococcal Vaccination Rates Among Older Adults in New York City and Los Angeles and Orange Counties.

Authors:  Stephanie C Tse; Laura C Wyatt; Chau Trinh-Shevrin; Simona C Kwon
Journal:  Prev Chronic Dis       Date:  2018-12-13       Impact factor: 2.830

4.  Pneumococcal Vaccination Coverage and Uptake Among Adults in Switzerland: A Nationwide Cross-Sectional Study of Vaccination Records.

Authors:  Kyra D Zens; Vasiliki Baroutsou; Jan S Fehr; Phung Lang
Journal:  Front Public Health       Date:  2022-01-31

Review 5.  Pneumococcus and the Elderly in Italy: A Summary of Available Evidence Regarding Carriage, Clinical Burden of Lower Respiratory Tract Infections and On-Field Effectiveness of PCV13 Vaccination.

Authors:  Andrea Orsi; Filippo Ansaldi; Cecilia Trucchi; Roberto Rosselli; Giancarlo Icardi
Journal:  Int J Mol Sci       Date:  2016-07-15       Impact factor: 5.923

6.  An analysis of factors associated with influenza, pneumoccocal, Tdap, and herpes zoster vaccine uptake in the US adult population and corresponding inter-state variability.

Authors:  Elizabeth M La; Laurel Trantham; Samantha K Kurosky; Dawn Odom; Emmanuel Aris; Cosmina Hogea
Journal:  Hum Vaccin Immunother       Date:  2017-12-15       Impact factor: 3.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.